CleanSpace Holdings Limited (ASX:CSX): Breath-Responsive Respirators and FY26 Operating Performance

Aditi Sarkar

14 October 2026 08:15 PM AEDT

CleanSpace Holdings Limited (ASX:CSX): Breath-Responsive Respirators and FY26 Operating Performance

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

CleanSpace designs and supplies powered respiratory protection for industrial and healthcare environments.
FY26 revenue reached A$19.8 million, broadly unchanged from the previous reporting period.
Gross margin was 75%, while the group reported a statutory loss after tax.
Its AGILE loose-fitting respirator obtained certification and launched in Europe and Australia/New Zealand.
Regional sales diverged, with European revenue increasing while North American sales declined.

CleanSpace Holdings Limited (ASX:CSX) designs, manufactures and supplies respiratory protection equipment for workers in industrial and healthcare settings. Its powered air-purifying respirators combine wearable filtration systems with technology that responds to breathing demand. During FY26, CleanSpace Holdings Limited (ASX:CSX) expanded its product range with AGILE while reporting broadly unchanged group revenue, a steady gross margin and uneven demand across international markets.

How Breath-Responsive Airflow Works

CleanSpace respirators use powered filtration to deliver clean air to the wearer. The company describes its systems as breath-responsive, meaning the airflow output adjusts with the user’s breathing rather than operating solely at a fixed delivery rate. This design is relevant to tasks that involve changing levels of physical exertion, when the wearer’s breathing pattern can vary throughout a shift.

The airflow system forms part of a complete respiratory protection arrangement that also depends on the appropriate mask or hood, correct filters, maintenance and operating procedures. CleanSpace Holdings Limited (ASX:CSX) markets solutions for industrial environments and healthcare applications, but the protective performance of any configuration remains dependent on its applicable certification, intended use and correct fitting or use.

FY26 Revenue, Margin and Earnings

For the financial year ended 30 June 2026, CleanSpace Holdings Limited (ASX:CSX) reported revenue of A$19.8 million, representing an increase of 0.3%. Respirator sales accounted for A$10.7 million, or 54% of group revenue. Consumables, masks, filters and accessories contributed A$9.1 million, or 46%. These categories help distinguish initial equipment sales from purchases associated with equipment already in service.

The FY26 gross margin was 75%. Operating expenses increased 3%, reflecting expenditure on marketing, research and development, and operational systems. The company recorded a statutory loss after tax of A$1.25 million. Reported EBITDA was A$1.46 million, although this included a gain relating to the remeasurement of a loan; operating EBITDA excluding that item remained negative.

Europe accounted for A$12.9 million in revenue during FY26, compared with A$2.2 million in North America and A$4.7 million across Asia-Pacific and other markets. CleanSpace Holdings Limited (ASX:CSX) reported cash at bank of A$10.1 million at year-end. The figures show that the group’s results were affected by differing regional trading conditions rather than a uniform pattern across markets.

AGILE Launch and Commercial Execution

In its August 2026 results announcement, CleanSpace highlighted certification and the launch of its AGILE loose-fitting powered air-purifying respirator in Europe and Australia/New Zealand. A loose-fitting system broadens the company’s equipment offering alongside existing mask-based products. Commercial adoption will depend on distributor activity, customer evaluation, workplace suitability and product availability.

For CleanSpace Holdings Limited (ASX:CSX), the launch connects engineering development with the practical requirements of respiratory protection programs. Its disclosed operating priorities include broadening distribution and building customer awareness in target markets.

Operating Factors and Limitations

Respiratory equipment providers face product-certification obligations, competitive procurement processes and demands for ongoing consumables supply. Sales also depend on workplace safety budgets and the timing of customer orders. CleanSpace’s FY26 disclosures identified regulatory and economic uncertainty as influences on the trading environment. Product innovation alone does not establish the timing or scale of future orders.

Key Insights

CleanSpace Holdings Limited (ASX:CSX) combines respiratory equipment design with ongoing sales of filters and accessories. Its FY26 results show a stable gross margin and a new product launch, alongside a statutory loss and uneven regional revenue. The distinction between accounting EBITDA and recurring operating EBITDA, together with adoption of AGILE and demand across regions, provides context for its 2026 operational position.

FAQs

Q: What does CleanSpace Holdings manufacture?

A:It designs and sells powered air-purifying respirators and related respiratory protection components.

Q: What was the company’s FY26 revenue?

A:CleanSpace reported A$19.8 million in revenue for the year ended 30 June 2026.

Q: What is breath-responsive airflow?

A:It is a system that adjusts powered airflow in response to a wearer’s breathing demand.

Q: What is AGILE?

A:AGILE is the company’s loose-fitting powered air-purifying respirator launched in selected regions during FY26.

Q: Did CleanSpace report a statutory profit in FY26?

A:No. It reported a statutory loss after tax of approximately A$1.25 million.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.